Amgen Inc. (AMGN) Stock Analysis
Latest ClaritX AI analysis ·
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infectio
| Metric | Value |
|---|---|
| Price | $402.60 |
| Market cap | $217.3B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ClaritX AI score | 83/100 |
| Price/Book | 18.60 |
| Dividend yield | 2.47% |
| Beta | 0.41 |
AI verdict
Amgen Inc. (AMGN) continues to present a compelling asymmetric risk-reward profile, acting as an elite defensive anchor with significant pipeline optionality. Currently trading at $402.60, the equity is stationed approximately 9.94% below its absolute 52-week high of $447.03. This nearly 10% discount offers a durable entry point for long-term accumulators, especially considering the asset's ultra-low beta of 0.407. This mathematically guarantees that Amgen historically operates with less than half the systemic volatility of the broader S&P 500, thoroughly insulating portfolios from aggressive macroeconomic shocks while paying a highly secure 2.47% dividend yield. Fundamentally, the company remains an absolute cash-printing juggernaut, generating $18.84 in pure free cash flow per share and maintaining an elite 72.65% gross margin. While the heavily levered balance sheet—evidenced by a 4.90 debt-to-equity ratio—demands continuous monitoring, organic cash generation effortlessly covers both massive dividend obligations and debt servicing. Supported by flawless discounted cash flow models, steadfast insider retention of Q2 accumulations, and aggressive analyst price targets averaging $446.67, Amgen warrants a confident bullish posture for income and value-oriented investors. Rating 83/100
What this score has been worth
ClaritX scores AMGN 83 out of 100 (snapshot 2026-10-15).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 192 analyses that scored in the 80-84 band, the average forward return was -1.0% with a 46% win rate, -5.6pp against the S&P 500. That is a measured tendency across many names, not a forecast for AMGN — roughly 54% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.